Shares in Stratagene rose 15.9 percent for the trading week ended Tuesday, a week after its shares had gained 17.4 percent. The firm had seen its shares slump to a 52-week low of $3.98 in the month leading up to the turnaround, but investors are clearly showing that they believe the stock was undervalued. The firm’s shares, however, have a long way to go before matching the 52-week high of $11.41.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.